Diabetic Neuropathy Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : Jun-2020 | List of Tables : 96 | List of Figures : 116 | No. of Pages : 170 | Report Code : FACT4698MR |

Diabetic Neuropathy Market: Approval of Novel Drugs to Push Revenue Growth

Diabetes is one of the most common chronic conditions, affecting millions of people globally. Changing lifestyles and imbalanced diets are the major factors responsible for increased incidence of diabetes. As of 2019, nearly 1/10th of the world’s population suffered from diabetes. Consequently, there has been a surge in diabetic treatment, with key pharmaceutical companies investing heavily in developing anti-diabetic formulations.

The approval of novel drugs for the treatment of diabetic neuropathic pain has led to a major uptick in the diabetic drugs market. In 2015, the FDA approved Nucynta ER for the treatment of neuropathic pain caused by diabetes. Another drug, Lyrica, has also been approved for neuropathic pain treatment in 130 countries. On the back of these trends, the global diabetic neuropathy is anticipated to grow at a CAGR of 5.6% during the forecast period (2020-2025).

The recent COVID-19 pandemic is not anticipated to limit production of novel drugs or supplies of insulin to hospitals or pharmacies, attributed to increased functional capacity of manufacturing plants of leading players across the world. However, delays in processing orders may be anticipated.

Peripheral & Proximal Neuropathy to Register Major Usage of Diabetic Neuropathy Formulations

The peripheral neuropathy disorder segment is projected to find increased usage of diabetic neuropathy formulations. The scope for peripheral neuropathy drugs is poised to increase, as the treatment for peripheral neuropathy is currently confined on managing pain rather than regeneration of nerves. Moreover, under diagnoses of peripheral neuropathic patients will broaden prospects of these drugs. Projections indicate a positive CAGR of 5.9% and a market share greater than half.

However, proximal neuropathy disorders are anticipated to find substantial applications of diabetic neuropathy formulations. Proximal neuropathy is the most common disorder among type 2 diabetics. An increase in the patient pool suffering from proximal neuropathy is thus anticipated to drive diabetic neuropathy drugs and formulations for the disorder, capturing a market share of nearly one-fourth and expanding at a CAGR of 5.6% through 2025.

diabetic neuropathy market size us$ forecast by disorder type

For in-depth knowledge on analysis of the diabetic neuropathy market by disorder, connect with an expert analyst

North America to Reign Supreme, Asia Pacific Shows Lucrative Prospects

North America is anticipated to witness significant usage of diabetic neuropathy drugs during the forecast period. Increasing percentage of patients getting diagnosed and receiving treatment for diabetic neuropathy along with growing government investments in research for new drugs and therapies are anticipated to boost market growth prospects. For instance, the National Institute of Neurological Disorders and Stroke funded research on neuropathy. This includes clinical studies of genetics and natural history of hereditary neuropathies. North America’s market is poised to capture more than two-fifth of the global market revenue, expanding 1.4X during the forecast period.

Asia Pacific is projected to show lucrative growth opportunities, expanding 1.5X and capturing over one-fifth share of the global diabetic neuropathy market through 2025. A large patient pool and supportive government policies are driving the diabetic neuropathy market growth in Asia Pacific. Inadequate healthcare infrastructure and poor dietary habits are poised to motivate companies to conduct research and develop new pipeline drugs.

diabetic neuropathy market increment opportunity assessment by region

For valuable insights on each regional market for diabetic neuropathy, request a report sample

Development of Novel Molecules and Drugs Remains Key Growth Stimuli for Market Players

The global diabetic neuropathy market is highly consolidated in nature. The key market players are Arbor Pharmaceuticals, LLC, Pfizer, Inc., Janssen Global Services, LLC, NeuroMatrix, Inc., Depomed, Inc., and Eli Lilly. These companies primarily concentrate on developing new drugs within their pipeline, owing to increased need for treatment of diabetics.

Janssen Global Services, LLC, the pharmaceutical arm of Johnson & Johnson, manufactures diabetic neuropathy drugs such as NUCYNTA, NUCYNTA ER, Duragesic and INVOKANA. These drugs contain canagliflozin and tapentadol which are important for regulating blood sugar levels. Likewise, Pfizer, Inc. produces Lyrica EH, Celebrex, Lyrica IH and Tafamidis Meglumine.

Another prominent market player, Glenmark Pharmaceuticals Ltd., manufactures remoglifozin etabonate, belonging to the gliflozin class to treat type-2 diabetes. Additionally, the company has successfully out-licensed seven novel molecules to leading pharmaceutical giants such as Merck KGaA and remains the only company to execute multiple deals on novel molecules. An example of this is the development of the SGLT2 inhibitor which developed into remoglifozin.

COVID-19 Impact Analysis

Diabetic patients are indeed extremely vulnerable to serious complications, if infected by the COVID-19 virus. The infection can cause internal swelling and also increase inflammation among diabetic patients. It is, therefore, imperative for hospitals, clinics and surgical centers to ensure that such complications are mitigated by providing advanced medical care. Fortunately, leading manufacturers in the diabetes sector have reported that the COVID-19 is not having an impact on their current manufacturing and distribution capabilities for vital injections such as insulin.

Majority of the players conclude that a shortage of medicines is not anticipated in the forecast period, due to close monitoring of supply chain for potential impacts on sale of medicines. However, delays in processing of orders are projected, attributed to a shift to a remote workforce. Eli Lilly, a diabetic drug manufacturing company, has claimed that its production shall not be hampered as their insulin manufacturing sites across Europe and the United States remain operational amid increased precautions. The company has urged pharmacies receiving insulin supplies from it to place orders directly with the wholesalers in order to avoid a manufacturer backorder. Another player, Mankind (Afrezza) claims that its U.S. manufacturing plant is fully operational, thus assuring clients that their supplies wouldn’t be impacted. To summarize, the global COVID-19 pandemic is poised to have a negligible restraining impact on the production of diabetic drugs across all regions.

The Analyst’s Viewpoint

“The menace of diabetic neuropathy is indeed acute, affecting nearly 50% of adults with diabetes during their lifetime. A dearth of treatments reversing underlying nerve damage has spurred healthcare practitioners to increase their research and development to find a potential solution. Future projections largely indicate drug combinations serving the dual purpose of providing symptomatic pain relief and improvement in the quality of life as well as slowing the progression of the underlying neuropathic processes”.

Diabetic Neuropathy Market: Report Scope

The recent study on diabetic neuropathy market undertaken by Fact.MR offers a 5-year forecast for the period of 2020 to 2025, elaborating on key market dynamics such as drivers, restraints and opportunities in diabetic neuropathy treatment. In-depth analysis in terms of revenue and growth forecasts has been conducted across the following segments: disorder, treatment, and distribution channel.

A regional landscape has been mapped based on five key geographies (North America, Europe, Asia Pacific, Latin America and Middle East & Africa). Each regional profiling incorporates the abovementioned segments. In the end, a competitive landscape highlighting key company profiles and their strategies for market expansion have also been included. Overall, an optimistic scenario has been painted for the future expansion of the diabetic neuropathy market.

Global Diabetic Neuropathy Market - Scope of the Report

The recent study by Fact.MR on global diabetic neuropathy market offers a 5-year forecast for the period of 2020-2025. The study analyzes crucial trends that are currently determining the growth of the global diabetic neuropathy market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the manufacturing of diabetic neuropathy drugs. The study also provides dynamics that are responsible for influencing the future status of the global diabetic neuropathy market over the forecast period.

A detailed assessment of the global diabetic neuropathy market value chain, business execution, and supply chain across regional markets has been covered in the report. A list of prominent companies operating in the global diabetic neuropathy market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Diabetic Neuropathy Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the global diabetic neuropathy market across the globe.

A comprehensive estimate of the global diabetic neuropathy market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global diabetic neuropathy drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

Global Diabetic Neuropathy Market Segmentation

Fact.MR has studied the global diabetic neuropathy market with detailed segmentation on the basis of disorder, treatment, distribution channel and region.

Disorder

Treatment

Distribution Channel

Region

Peripheral Neuropathy

Drugs:

Analgesic:

Topical:

  • Capsaicin
  • Others

Opioid:

  • Morphine
  • Others

NSAIDs:

  • Ibuprofen
  • Naproxen
  • Others

Antidepressants:

TCAs:

  • Amitriptyline
  • Imipramine
  • Others

SNRIs:

  • Duloxetine
  • Others

SSRIs:

  • Citalopram
  • Paroxetine
  • Others

Anticonvulsant Drugs:

  • Gabapentin
  • Pregabalin
  • Topiramate
  • Others

Other Drugs

Hospitals

 

North America

Autonomic Neuropathy

Radiotherapy:

  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Others

Clinics

Europe

Proximal Neuropathy

Physiotherapy

Retail Pharmacy

Asia Pacific

Focal Neuropathy

 

Online Pharmacy

Latin America

 

 

 

Middle East & Africa (MEA)

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Global Diabetic Neuropathy Market: Size Evaluation

The global diabetic neuropathy market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for diabetic neuropathy market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent diabetic neuropathy market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Diabetic Neuropathy Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global diabetic neuropathy market report, which have helped deliver projections on regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the global diabetic neuropathy market during the forecast period.

Country-specific valuation on demand for diabetic neuropathy has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

Global Diabetic Neuropathy Market: In-Depth Analysis on Competitive Landscape

The report sheds light on leading manufacturers of the global diabetic neuropathy market along with their detailed profiles. Essential and up-to-date data and information related to the market performers, who are principally engaged in the production of diabetic neuropathy drugs, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global diabetic neuropathy market. Prominent manufacturers with established market presence in the global diabetic neuropathy market are Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Lupin Limited, Astellas Pharma Inc., Pfizer, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC, and Depomed, Inc.

1. Market Overview

    1.1. Market Coverage / Taxonomy 

    1.2. Market Definition / Scope / Limitations

2. Market Risks and Trends Assessment 

    2.1. Risk Assessment 

        2.1.1. COVID-19 Crisis and Impact on Diabetic Neuropathy Demand

        2.1.2. COVID-19 Crisis and Impact on Diabetic Neuropathy Cost 

        2.1.3. COVID-19 Impact Benchmark with Previous Crisis 

            2.1.3.1. Change in Diabetic Neuropathy Demand 

            2.1.3.2. Before and After COVID-19 Crisis (Projected)

            2.1.3.3. Before and After Sub-prime Crisis – 2008 (Actual)

            2.1.3.4. Change in Demand post Recovery Period (After Each Crisis)

        2.1.4. Impact on Market Value (US$ Mn)

            2.1.4.1. Likely Loss of Value in 2020

            2.1.4.2. Mid-term and Long Term Forecast

            2.1.4.3. Quarter by Quarter Demand and Recovery Assessment 

        2.1.5. Anticipated Demand and Value Recovery Curve

            2.1.5.1. Likelihood of U-Shape Recovery

            2.1.5.2. Likelihood of L-Shape Recovery

        2.1.6. Recovery Period Assessment by Key Countries

        2.1.7. Recovery Assessment by Key Market Segments

        2.1.8. Action Points and Recommendation for Suppliers

    2.2. Key Trends Impacting the Market

3. Market Background and Foundation Data Points 

    3.1. Global Healthcare Market Overview

    3.2. Healthcare Spending Analysis, By Key Countries

    3.3. Global Diabetes Patients Scenario, BY Key Countries

    3.4. Per Capita Spending on Diabetes, BY Key Countries

    3.5. Recent Developments in Diabetic Neuropathy Industry

    3.6. Growth and Development Patterns in Diabetic Neuropathy Market

    3.7. Market White Space Assessment And Opportunity Analysis

    3.8. Recent Development in Diabetic Neuropathy Market, By Market Players

    3.9. Competitive Scenario and Trends

    3.10. Diabetic Neuropathy Market Concentration Rate

        3.10.1. List of Emerging, Prominent and Leading Players 

        3.10.2. Mergers & Acquisitions

    3.11. Scenario Forecast 

and in optimistic, likely, and conservative market conditions) 

    3.12. Policy and Regulatory Landscape

    3.13. Macro-Economic Factors

    3.14. Forecast Factors - Relevance & Impact

    3.15. Market Dynamics

        3.15.1. Market Driving Factors and Impact Assessment

        3.15.2. Prominent Market Challenges and Impact Assessment

        3.15.3. Diabetic Neuropathy Market Opportunities

        3.15.4. Prominent Trends in the Global Market & Their Impact Assessment

4. Key Success Factors 

    4.1. Diabetic Neuropathy Adoption / Usage Analysis

    4.2. Disorder USPs / Features

    4.3. Others (Discussed in Report)

5. Global Diabetic Neuropathy Market Value Analysis 2015-2019 and Forecast, 2020-2025

    5.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

    5.2. Current and Future Market Value (US$ Mn) Projections, 2020-2025

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Global Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025, By Disorder 

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Mn) Analysis By Disorder, 2015-2019

    6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disorder, 2020-2025

        6.3.1. Peripheral Neuropathy

        6.3.2. Autonomic Neuropathy

        6.3.3. Proximal Neuropathy

        6.3.4. Focal Neuropathy

    6.4. Market Attractiveness Analysis By Disorder 

7. Global Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025, By Treatment

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2015-2019

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2020-2025

        7.3.1. Drug

            7.3.1.1. Analgesic

                7.3.1.1.1. Topical

                    7.3.1.1.1.1. Capsaicin

                    7.3.1.1.1.2. Others

                7.3.1.1.2. Opioids

                    7.3.1.1.2.1. Morphine

                    7.3.1.1.2.2. Others

                7.3.1.1.3. NSAIDs

                    7.3.1.1.3.1. Ibuprofen

                    7.3.1.1.3.2. Naproxen

                    7.3.1.1.3.3. Others

            7.3.1.2. Antidepressant

                7.3.1.2.1. TCAs

                    7.3.1.2.1.1. Amitriptyline

                    7.3.1.2.1.2. Imipramine

                    7.3.1.2.1.3. Others 

                7.3.1.2.2. SNRIs

                    7.3.1.2.2.1. Duloxetine

                    7.3.1.2.2.2. Others

                7.3.1.2.3. SSRIs

                    7.3.1.2.3.1. Citalopram

                    7.3.1.2.3.2. Paroxetin

                    7.3.1.2.3.3. Others

            7.3.1.3. Anticonvulsants

                7.3.1.3.1. Gabapentin

                7.3.1.3.2. Pregabalin

                7.3.1.3.3. Topimarate

                7.3.1.3.4. Others

                7.3.1.3.5. Other Drugs

        7.3.2. Radiotherapy

            7.3.2.1. TENS

            7.3.2.2. Others

        7.3.3. Physiotherapy

    7.4. Market Attractiveness Analysis By Treatment

8. Global Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015-2019

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020-2025

        8.3.1. Hospitals

        8.3.2. Clinics

        8.3.3. Retail Pharmacy 

        8.3.4. Online Pharmacy

    8.4. Market Attractiveness Analysis By Distribution Channel

9. Global Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025, by Region

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2019

    9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2025

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. Asia Pacific 

        9.3.5. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2015-2019 and Forecast 2020-2025

    10.1. Introduction

    10.2. Pricing Analysis

    10.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2019

    10.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2025

        10.4.1.  By Country

            10.4.1.1. U.S.

            10.4.1.2. Canada

        10.4.2. By Disorder

        10.4.3. By Distribution Channel

        10.4.4. By Treatment

    10.5. Market Attractiveness Analysis

        10.5.1. By Country

        10.5.2. By Disorder

        10.5.3. By Distribution Channel

        10.5.4. By Treatment

11. Latin America Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025

    11.1. Introduction

    11.2. Pricing Analysis

    11.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2019

    11.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2025

        11.4.1.  By Country

            11.4.1.1. Brazil

            11.4.1.2. Mexico

            11.4.1.3. Rest of Latin America

        11.4.2. By Disorder

        11.4.3. By Distribution Channel

        11.4.4. By Treatment 

    11.5. Market Attractiveness Analysis

        11.5.1. By Country

        11.5.2. By Disorder

        11.5.3. By Distribution Channel

        11.5.4. By Treatment

12. Europe Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025

    12.1. Introduction

    12.2. Pricing Analysis

    12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2019

    12.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2025

        12.4.1.  By Country

            12.4.1.1. Germany

            12.4.1.2. France

            12.4.1.3. Italy

            12.4.1.4. Spain

            12.4.1.5. U.K.

            12.4.1.6. Russia

            12.4.1.7. Rest of Europe

        12.4.2. By Disorder

        12.4.3. By Distribution Channel

        12.4.4. By Treatment

    12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Disorder

        12.5.3. By Distribution Channel

        12.5.4. By Treatment

13. Asia Pacific Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2019

    13.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2025

        13.4.1.  By Country

            13.4.1.1. China

            13.4.1.2. Japan

            13.4.1.3. India

            13.4.1.4. Australia & New Zealand

            13.4.1.5. Rest of Asia Pacific

        13.4.2. By Disorder

        13.4.3. By Distribution Channel

        13.4.4. By Treatment

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Disorder

        13.5.3. By Distribution Channel

        13.5.4. By Treatment

14. Middle East and Africa Diabetic Neuropathy Market Analysis 2015-2019 and Forecast 2020-2025

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2019

    14.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2025

        14.4.1.  By Country

            14.4.1.1. GCC Countries

            14.4.1.2. South Africa

            14.4.1.3. Rest of Middle East and Africa

        14.4.2. By Disorder

        14.4.3. By Distribution Channel

        14.4.4. By Treatment

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Disorder

        14.5.3. By Distribution Channel

        14.5.4. By Treatment

15. Market Structure Analysis

    15.1. Market Analysis by Tier of Companies 

    15.2. Market Concentration

    15.3. Market Share Analysis of Top Players

    15.4. Market Presence Analysis

        15.4.1. By Regional footprint of Players

        15.4.2. Disorder footprint by Players

        15.4.3. Channel footprint by Players

16. Competition Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Competition Deep Dive (Indicative List)

        16.3.1. Johnson & Johnson (Janssen Global Services, LLC)

            16.3.1.1. Overview

            16.3.1.2. Disorder Portfolio

            16.3.1.3. Sales Footprint

            16.3.1.4. Strategy Overview

        16.3.2. Boehringer Ingelheim GmbH

            16.3.2.1. Overview

            16.3.2.2. Disorder Portfolio

            16.3.2.3. Sales Footprint

            16.3.2.4. Strategy Overview

        16.3.3. NeuroMetrix, Inc

            16.3.3.1. Overview

            16.3.3.2. Disorder Portfolio

            16.3.3.3. Sales Footprint

            16.3.3.4. Strategy Overview

        16.3.4. Eli Lilly and Company

            16.3.4.1. Overview

            16.3.4.2. Disorder Portfolio

            16.3.4.3. Sales Footprint

            16.3.4.4. Strategy Overview

        16.3.5. GlaxoSmithKline plc

            16.3.5.1. Overview

            16.3.5.2. Disorder Portfolio

            16.3.5.3. Sales Footprint

            16.3.5.4. Strategy Overview

        16.3.6. Lupin Limited

            16.3.6.1. Overview

            16.3.6.2. Disorder Portfolio

            16.3.6.3. Sales Footprint

            16.3.6.4. Strategy Overview

        16.3.7. Pfizer Inc

            16.3.7.1. Overview

            16.3.7.2. Disorder Portfolio

            16.3.7.3. Sales Footprint

            16.3.7.4. Strategy Overview

        16.3.8. Astellas Pharma Inc

            16.3.8.1. Overview

            16.3.8.2. Disorder Portfolio

            16.3.8.3. Sales Footprint

            16.3.8.4. Strategy Overview

        16.3.9. Glenmark Pharmaceuticals Ltd

            16.3.9.1. Overview

            16.3.9.2. Disorder Portfolio

            16.3.9.3. Sales Footprint

            16.3.9.4. Strategy Overview

        16.3.10. Arbor Pharmaceuticals, LLC

            16.3.10.1. Overview

            16.3.10.2. Disorder Portfolio

            16.3.10.3. Sales Footprint

            16.3.10.4. Strategy Overview

        16.3.11. Depomed, Inc

            16.3.11.1. Overview

            16.3.11.2. Disorder Portfolio

            16.3.11.3. Sales Footprint

            16.3.11.4. Strategy Overview

        16.3.12. Other Prominent Players 

            16.3.12.1. Overview

            16.3.12.2. Disorder Portfolio

            16.3.12.3. Sales Footprint

            16.3.12.4. Strategy Overview

17. Assumptions and Acronyms Used

18. Research Methodology

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Diabetic Neuropathy Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2020 to 2025